Pharmacyte Biotech Inc (PMCB) 0.0570 $PMCB PharmaCyte

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pharmacyte Biotech Inc (PMCB) 0.0570 $PMCB

PharmaCyte Biotech Receives Patent Protection of the Melligen Cells to Treat Diabetes
GlobeNewswire - Thu Jul 14, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the U.S. Patent and Trademark Office (USPTO) has granted patent protection of the Melligen cells that are a part of PharmaCyte's therapy for Type 1 and insulin-dependent Type 2 diabetes.

Wall Street Targets Funding Opportunities for Multi-Billion Dollar Cannabis & Legal Marijuana Operations
PR Newswire - Wed Jul 13, 7:45AM CDT
It is estimated that the expense to start a legal marijuana business in the U.S. could cost more than $1Million, according to the Marijuana Business Association. The absence of commercial credit available for the industry in past has opened up opportunities for institutions & private lenders who want to step into the cannabis industry with the average loan estimated at $750,000. Microsoft Corp. (NASDAQ: MSFT) recently became the first major company to announce its participation in the cannabis/marijuana sector, as the computer giant has partnered with Kind Financial, which helps businesses and government agencies track sales of legalized marijuana.
GWPH: 90.39 (-0.61), MSFT: 53.70 (-0.04)

PharmaCyte Biotech to Hold Shareholder Call
GlobeNewswire - Mon Jul 11, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Chief Executive Officer, Kenneth L. Waggoner, will conduct a shareholder conference call at 4:30 p.m. EDT on Thursday, July 28, 2016.

PharmaCyte Biotech Uses "Artificial Liver" to Treat Advanced Pancreatic Cancer
Marketwire Canada - Thu Jul 07, 8:03AM CDT
NEW YORK, NY--(Marketwired - July 07, 2016) - PharmaCyte Biotech's (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, is being used in treatments for both cancer and diabetes. For diabetes, the company's therapy, which is made up of pinhead-sized, porous capsules filled with insulin producing cells, will create an "artificial pancreas" for type 1 diabetics and insulin-dependent type 2 diabetics that no longer produce their own insulin. Meanwhile, for cancer, the company's therapy is made up of those same pinhead-sized, porous capsules; however, for advanced pancreatic cancer, they're filled with genetically modified cells that act as a type of "artificial liver."

Cannabis Attracting Big Business Operators as Multi-Billion Dollar Cannabis/Marijuana Industry Continues to Swell
PR Newswire - Wed Jul 06, 7:30AM CDT
Revenue forecasts for the cannabis industry in the United States continue to skyrocket as more states move towards legalization and companies develop innovative services and products to maximize earning potential. More and more big business entities are becoming involved in the lucrative cannabis sector as marijuana projects and opportunities explode in U.S.
XXII: 0.86 (unch), INSY: 14.98 (+0.22)

PharmaCyte's Research on Medical Uses of Cannabinoids Supported by Recent Scientific Article
GlobeNewswire - Tue Jul 05, 8:40AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that a recently published scientific article supports PharmaCyte's ongoing research efforts that concern medical uses for constituents of Cannabis known as cannabinoids. The article titled "Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids" was published in the journal, Aging and Mechanisms of Disease and appeared online on June 23, 2016. The article can be viewed in its entirety at http://www.nature.com/articles/npjamd201612

PharmaCyte Biotech Releases Medical and Scientific Discussion from 2016 ASCO Annual Meeting
GlobeNewswire - Thu Jun 23, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced the release of 5 video presentations that captured PharmaCyte's medical and scientific discussion with oncologists interested in participating in PharmaCyte's Phase 2b clinical trial in advanced, inoperable pancreatic cancer. The discussion session was by invitation only during the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

PharmaCyte Biotech CEO Interviewed Live During Marcum MicroCap Conference
GlobeNewswire - Mon Jun 20, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, was interviewed by Stock News Now (SNN) at the 5th Annual Marcum MicroCap Conference in New York City. The SNNLive video interview can be viewed by clicking on the following link: www.PharmaCyte.com/Media.

PharmaCyte Biotech to Present Cancer and Diabetes Therapies at 2016 BIO International Convention
GlobeNewswire - Tue Jun 07, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will present PharmaCyte's therapies for cancer and diabetes at this year's BIO International Convention (BIO). Meetings have been scheduled with big pharma potential investors, strategic partners and the media. The 2016 BIO International Convention is being held at the Moscone Center in San Francisco June 6-9, 2016.

PharmaCyte Biotech Officers to Attend Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Fri Jun 03, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its entire senior management team will attend the American Society of Clinical Oncology's (ASCO) 52nd annual meeting to be held June 3-7, 2016, at McCormick Place in Chicago. The theme of this year's meeting is "Collective Wisdom - The Future of Patient Centered Care and Research."

OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.

PharmaCyte Biotech's CEO Featured Speaker at Marcum MicroCap Conference
GlobeNewswire - Tue May 31, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the Chief Executive Officer of PharmaCyte will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel. The presentation is scheduled to begin at 9:30 a.m. EDT and will be available via a live webcast. To access the webcast go to http://wsw.com/webcast/marcum4/pmcb.

PharmaCyte Biotech to Present Clinical Trial at Marcum MicroCap, ASCO and BIO International Conferences
GlobeNewswire - Thu May 26, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel.

PharmaCyte Biotech to Engage Principal Investigator for Clinical Trial in Pancreatic Cancer
GlobeNewswire - Tue May 24, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that PharmaCyte has commenced its search for a Principal Investigator for its Phase 2b clinical trial in advanced pancreatic cancer. PharmaCyte will be meeting with potential candidates at this year's annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, June 3-7, 2016.

PharmaCyte Biotech Receives 'Notice of Allowance' for Patent Protection of the Melligen Cells to Treat Diabetes
GlobeNewswire - Thu May 12, 8:34AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that a Notice of Allowance was received from the U.S. Patent and Trademark Office (USPTO) for patent protection of the human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body (Melligen cells). PharmaCyte plans to encapsulate Melligen cells using the Cell-in-a-Boxtechnology.

PharmaCyte Biotech Clears Major Milestone on Path to FDA Clinical Trial
Marketwire Canada - Thu May 05, 8:15AM CDT
NEW YORK, NY--(Marketwired - May 05, 2016) -  PharmaCyte Biotech (OTCQB: PMCB) has now reached a point in its life cycle where it is ready to start working with the U.S. FDA to get the company's Phase 2b clinical trial in advanced pancreatic cancer underway. Let that sink in for a moment. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, has taken up the mantle to move the company's signature technology, Cell-in-a-Box®, to the clinic. And now, three short years later, he has the small biotech on the doorstep of what could be an eye-opening clinical trial to treat pancreatic cancer patients.

PharmaCyte Biotech Appoints Former Johnson & Johnson Executive as Senior Business Development Advisor
GlobeNewswire - Tue May 03, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that it has appointed Dr. Sanjay Batra as its Senior Business Development Advisor.
JNJ: 123.00 (-0.18)

PharmaCyte Biotech's Live-Cell Encapsulation Facility is Commissioned for GMP Manufacture
GlobeNewswire - Mon Apr 25, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that the encapsulation facility for its pancreatic cancer therapy is ready to manufacture PharmaCyte's biologic product under current Good Manufacturing Practices (GMP) standards. The facility will be used to encapsulate the live cells used for PharmaCyte's pancreatic cancer therapy. The assessment was issued by Chamow & Associates, the biopharmaceutical consulting firm that specializes in the inspection of facilities for GMP compliance.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 360

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 251

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 41

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 120

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 95

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 229

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 79

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Growth Ahead for Luxury Apparel Market Forecast

Updated Category News Views 132

Luxury Apparel Market Set for Significant Growth The global luxury apparel market is poised for substantial growth, projected to expand by USD 25.2 billion in the upcoming years, specifically from 2025 to 2029. This growth trajectory is largely attributed to increasing disposable income in emerging economies, where luxury sportswear is becoming increasingly popular. With...

Continue Reading
Food Emulsifiers Market Set for Significant Growth

Updated Category News Views 175

Market Potential: Scratching the Surface Who would have thought that a tiny ingredient like food emulsifiers would hold such massive sway in the food industry? Well, here we are, peering into a future where the global food emulsifiers market could skyrocket to a whopping USD 5.07 billion by 2035. That's right, these unsung heroes of the food world are shaking things up,...

Continue Reading
RBC Capital Highlights Challenges for Permanent TSB Stock

Updated Category News Views 79

RBC Capital's Cautious Stance on Permanent TSB Group Holdings Recently, RBC Capital has taken a critical look at Permanent TSB Group Holdings PLC and has initiated coverage with an Underperform rating and a price target set at €1.00. This decision has raised eyebrows amongst investors and analysts alike, as it indicates significant concerns regarding the bank's...

Continue Reading
Revolutionizing Equine Insurance with AI Technology Today

Updated Category News Views 208

Innovating Equine Insurance with AI Solutions Halo AI, the pioneering platform for equine performance prediction and insurance, is redefining risk management within the equine industry. Unveiling its groundbreaking offerings, Halo integrates predictive analytics with flexible insurance cover, paving the way for a revolutionary approach to ensuring horses' welfare and...

Continue Reading
Insights on Managerial Trading Activities in Columbus A/S

Updated Category News Views 197

Understanding Recent Managerial Trading at Columbus A/S Columbus A/S, a company that specializes in providing technology and consultancy services, has recently made significant disclosures as per regulatory requirements. The firm is dedicated to transparency, especially in instances where trading activities involve managerial roles. This commitment to openness fosters...

Continue Reading